Simvastatin induces impairment in skeletal muscle while heart is protected

Biochemical and Biophysical Research Communications

Volumn 338, Issue 3, 2005, Pages 1426-1434

  Sirvent, Pascal ^a,b   Bordenave, Sylvain ^b   Vermaelen, Marianne ^b   Roels, Belle ^c   Vassort, Guy ^a   Mercier, Jacques ^b   Raynaud, Eric ^b   Lacampagne, Alain ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

^c Faculty of Sport Sciences   (France)

Author keywords

Calcium; Human skeletal muscle; Hypercholesterolemia; Mitochondria; Monocarboxylate transporter; Myotoxicity; Rat cardiomyocytes; Satins

Indexed keywords

MONOCARBOXYLATE TRANSPORTER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIMVASTATIN;

ADULT; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CELL DEATH; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME INHIBITION; FLEXOR MUSCLE; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN TISSUE; MALE; MUSCLE CELL; MYOPATHY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RESPIRATORY CHAIN; SKELETAL MUSCLE;

ANIMALS; CALCIUM; CELL MEMBRANE; CYTOSOL; ELECTRON TRANSPORT; HEART; HOMEOSTASIS; HUMANS; MALE; MITOCHONDRIA, HEART; MUSCLE, SKELETAL; MYOCARDIUM; RATS; RATS, WISTAR; SIMVASTATIN;

ANIMALIA;

EID: 27744605052     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.10.108     Document Type: Article

References (32)

1. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
2. C.J. Vaughan, and A.M. Gotto Jr. Update on statins: 2003 Circulation 110 2004 886 892
3. J.A. Tobert, G.D. Bell, J. Birtwell, I. James, W.R. Kukovetz, J.S. Pryor, A. Buntinx, I.B. Holmes, Y.S. Chao, and J.A. Bolognese Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers J. Clin. Invest. 69 1982 913 919
4. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction, Am. J. Cardiol. 71 (1993) 393-400.
5. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, and E. Braunwald The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N. Engl. J. Med. 339 (1998) 1349-1357.
7. M. Takemoto, K. Node, H. Nakagami, Y. Liao, M. Grimm, Y. Takemoto, M. Kitakaze, and J.K. Liao Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J. Clin. Invest. 108 2001 1429 1437
8. J.K. Liao Isoprenoids as mediators of the biological effects of statins J. Clin. Invest. 110 2002 285 288
9. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39 III43
10. J.P. Halcox, and J.E. Deanfield Beyond the laboratory: clinical implications for statin pleiotropy Circulation 109 2004 II42 II48
11. M. Ucar, T. Mjorndal, and R. Dahlqvist HMG-CoA reductase inhibitors and myotoxicity Drug Safety 22 2000 441 457
12. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
13. 2+ signaling alteration in skeletal muscle Biochem. Biophys. Res. Commun. 329 2005 1067 1075
14. 2+-sensitizing properties in cardiac myocytes Br. J. Pharmacol. 139 2003 99 108
15. 2+ waves in saponin-permeabilized rat ventricular myocytes J. Physiol. 521 Pt 3 1999 575 585
16. C. Thomas, P. Sirvent, S. Perrey, E. Raynaud, and J. Mercier Relationships between maximal muscle oxidative capacity and blood lactate removal after supramaximal exercise and fatigue indexes in humans J. Appl. Physiol. 97 2004 2132 2138
17. V.A. Saks, V.I. Veksler, A.V. Kuznetsov, L. Kay, P. Sikk, T. Tiivel, L. Tranqui, J. Olivares, K. Winkler, F. Wiedemann, and W.S. Kunz Permeabilized cell and skinned fiber techniques in studies of mitochondrial function in vivo Mol. Cell. Biochem. 184 1998 81 100
18. M. Jakobisiak, S. Bruno, J.S. Skierski, and Z. Darzynkiewicz Cell cycle-specific effects of lovastatin Proc. Natl. Acad. Sci. USA 88 1991 3628 3632
19. K. Nagasawa, K. Nagai, Y. Sumitani, Y. Moriya, Y. Muraki, K. Takara, N. Ohnishi, T. Yokoyama, and S. Fujimoto Monocarboxylate transporter mediates uptake of lovastatin acid in rat cultured mesangial cells J. Pharm. Sci. 91 2002 2605 2613
20. A.P. Halestrap, and N.T. Price The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation Biochem. J. 343 Pt. 2 1999 281 299
21. J.E. Manning Fox, D. Meredith, and A.P. Halestrap Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle J. Physiol. 529 Pt. 2 2000 285 293
22. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, and A.M. Gotto Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study Jama 279 1998 1615 1622
23. W.R. Garnett Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors Am. J. Health Syst. Pharm. 52 1995 1639 1645
24. Y. Berland, H. Vacher Coponat, C. Durand, M. Baz, R. Laugier, and J.L. Musso Rhabdomyolysis with simvastatin use Nephron 57 1991 365 366
25. M.A. Omar, J.P. Wilson, and T.S. Cox Rhabdomyolysis and HMG-CoA reductase inhibitors Ann. Pharmacother. 35 2001 1096 1107
26. J. Sacher, L. Weigl, M. Werner, C. Szegedi, and M. Hohenegger Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells J. Pharmacol. Exp. Ther. 314 2005 1032 1041
27. J.P. Mazat, T. Letellier, F. Bedes, M. Malgat, B. Korzeniewski, L.S. Jouaville, and R. Morkuniene Metabolic control analysis and threshold effect in oxidative phosphorylation: implications for mitochondrial pathologies Mol. Cell. Biochem. 174 1997 143 148
28. M. Bergman, H. Salman, M. Djaldetti, S. Alexandrova, I. Punsky, and H. Bessler Ultrastructure of mouse striated muscle fibers following pravastatin administration J. Muscle Res. Cell Motil. 24 2003 417 420
29. D. Hudman, R.D. Rainbow, C.L. Lawrence, and N.B. Standen The origin of calcium overload in rat cardiac myocytes following metabolic inhibition with 2,4-dinitrophenol J. Mol. Cell. Cardiol. 34 2002 859 871
30. A. Bonen Lactate transporters (MCT proteins) in heart and skeletal muscles Med. Sci. Sports Exerc. 32 2000 778 789
31. M. Takeda, R. Noshiro, M.L. Onozato, A. Tojo, H. Hasannejad, X.L. Huang, S. Narikawa, and H. Endou Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors Eur. J. Pharmacol. 483 2004 133 138
32. H. Lullmann, and A. Ziegler Calcium, cell membrane, and excitation-contraction coupling J. Cardiovasc. Pharmacol. 10 Suppl. 1 1987 S2 S8